Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Autoimmune Disorders

Free Subscription Articles published in Brain Retrieve available abstracts of 56 articles: HTML format

Single Articles

November 2025
1. MACESKI AM, Benkert P, Einsiedler M, Schaedelin S, et al
   GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.
   Brain. 2025 Nov 14:awaf433. doi: 10.1093.
   PubMed     Abstract available
   
   
   October 2025
2. MASI G, Chen K, Bayer AC, Bayarri-Olmos R, et al
   IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology.
   Brain. 2025 Oct 28:awaf410. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. THEMISTOCLEOUS A, Middleton SJ, Dawes JM
   Understanding sensory abnormalities in fibromyalgia through autoantibodies.
   Brain. 2025 Oct 13:awaf384. doi: 10.1093.
   PubMed    
   
   
   
4. BELLANTI R, Iserte AC, Johnson CB, Goodfellow J, et al
   Enhanced adenoviral reactivity in Guillain-Barre syndrome after SARS-CoV-2 infection and vaccination.
   Brain. 2025 Oct 7:awaf376. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. MUKHERJEE T, McMurran CE, Holland J, Daruwalla C, et al
   Ageing and remyelination failure in people with multiple sclerosis.
   Brain. 2025 Oct 6:awaf373. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. ASHIKAWA Y, Itokazu T, Yamashita T
   Astrocyte regeneration via FGF8-DBX1 signalling facilitates recovery in neuromyelitis optica rats.
   Brain. 2025;148:3763-3777.
   PubMed     Abstract available
   
   
   September 2025
7. FURLAN R, Schaedelin S, Frederiksen JL, Watanabe M, et al
   Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.
   Brain. 2025 Sep 24:awaf345. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. FEINSTEIN A, Bar-Or A, Benedict RHB, Filippi M, et al
   Is multiple sclerosis-related depression different from depression in general? The data for and against.
   Brain. 2025 Sep 9:awaf319. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. ESSER D, Muller-Miny L, Heming M, Paunovic M, et al
   Activated alphabeta T and reduced mucosa-associated invariant T cells in LGI1- and CASPR2-encephalitis.
   Brain. 2025;148:3170-3183.
   PubMed     Abstract available
   
   
   August 2025
10. PAPE K, Hanuscheck N, Schmaul S, Kneilmann F, et al
    Role of CD5 signalling for pro-inflammatory Th17 response in multiple sclerosis.
    Brain. 2025 Aug 25:awaf268. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. RODRIGUES P, Frare JM, Ruviaro NA, Peres DS, et al
    Advanced oxidation protein products activated TRPA1 in a neuropathic multiple sclerosis model.
    Brain. 2025 Aug 17:awaf306. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. CHIEK TEOH CS, Dubey SG, Handel AE
    Rethinking corticosteroid therapy in autoimmune neurology.
    Brain. 2025 Aug 11:awaf292. doi: 10.1093.
    PubMed    
    
    
    
13. KALINCIK T, Sharmin S, Roos I, Freedman MS, et al
    Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.
    Brain. 2025 Aug 4:awaf286. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. ABDELHAK A, Cordano C, Duncan GJ, Emberley K, et al
    Markers of axonal injury in blood and tissue triggered by acute and chronic demyelination.
    Brain. 2025;148:3011-3020.
    PubMed     Abstract available
    
    
    
15. NISHIGORI R, Hamatani M, Yoshitomi H, Kimura K, et al
    CD21lo B-cell subsets are recruited to the central nervous system in acute neuromyelitis optica.
    Brain. 2025;148:2995-3010.
    PubMed     Abstract available
    
    
    June 2025
16. CUNNIFFE NG
    Extending the role of neurofilament light in multiple sclerosis beyond measuring irreversible neurodegeneration.
    Brain. 2025 Jun 9:awaf224. doi: 10.1093.
    PubMed    
    
    
    
17. MAUDES E, Planaguma J, Marmolejo L, Radosevic M, et al
    Neuro-immunobiology and treatment assessment in a mouse model of anti-NMDAR encephalitis.
    Brain. 2025;148:2023-2037.
    PubMed     Abstract available
    
    
    May 2025
18. IRANI SR
    Models of autoantibody mediated diseases: actively nearing the human gold standard.
    Brain. 2025 May 23:awaf160. doi: 10.1093.
    PubMed    
    
    
    
19. FENG YF, Zeng ZK, Ni Y, Hu Y, et al
    Parvalbumin neurons mediate neurological phenotypes of anti-NMDAR encephalitis.
    Brain. 2025;148:1652-1664.
    PubMed     Abstract available
    
    
    
20. GIOVANNONI G, James L, Adeniran AA, Gold J, et al
    The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis.
    Brain. 2025 May 6:awaf170. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
21. NOBILE-ORAZIO E, Cocito D, Manganelli F, Fazio R, et al
    Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial.
    Brain. 2025;148:1112-1121.
    PubMed     Abstract available
    
    
    March 2025
22. THOMMA RCM, Halstead SK, de Koning LC, Wiegers EEJA, et al
    Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barre syndrome.
    Brain. 2025 Mar 17:awaf102. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2025
23. GIOVANNONI G
    EBV-specific T-cell responses are telling us something important about multiple sclerosis.
    Brain. 2025 Jan 27:awaf027. doi: 10.1093.
    PubMed    
    
    
    December 2024
24. CHEN JQA, McNamara NB, Engelenburg HJ, Jongejan A, et al
    Distinct transcriptional changes distinguish efficient and poor remyelination in multiple sclerosis.
    Brain. 2024 Dec 24:awae414. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. ANDRODIAS G, Lunemann JD, Maillart E, Amato MP, et al
    De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.
    Brain. 2024 Dec 21:awae409. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. COLES A
    A blood test to predict prognosis in multiple sclerosis?
    Brain. 2024;147:3969.
    PubMed    
    
    
    November 2024
27. SUN J, Guo M, Chai L, Xu S, et al
    Distinct virtual histology of grey matter atrophy in four neuroinflammatory diseases.
    Brain. 2024;147:3906-3917.
    PubMed     Abstract available
    
    
    September 2024
28. BERGNER CG, van der Meer F, Franz J, Vakrakou A, et al
    BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis.
    Brain. 2024 Sep 25:awae293. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
29. MONREAL E, Fernandez-Velasco JI, Alvarez-Lafuente R, Sainz de la Maza S, et al
    Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
    Brain. 2024 Aug 5:awae260. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. ZHAO M, Lynch DR, Irani SR
    Autoimmune 'secondary synaptopathies': do NMDAR antibodies cause a primary extra-synaptopathy?
    Brain. 2024;147:2601-2603.
    PubMed     Abstract available
    
    
    July 2024
31. FILIPPI M, Preziosa P, Barkhof F, Ciccarelli O, et al
    The ageing central nervous system in multiple sclerosis: the imaging perspective.
    Brain. 2024 Jul 24:awae251. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. HOLM RP, Wandall-Holm MF, Magyari M
    Multiple sclerosis in Denmark (1950-2023): mean age, sex distribution, incidence and prevalence.
    Brain. 2024 Jul 20:awae245. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. TAYLOR BV, Ponsonby AL, Stein M, Lucas R, et al
    Reply: Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size.
    Brain. 2024 Jul 19:awae246. doi: 10.1093.
    PubMed    
    
    
    
34. SCHNEIDER-HOHENDORF T, Wunsch C, Falk S, Raposo C, et al
    Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation.
    Brain. 2024 Jul 18:awae244. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. CORSTEN CEA, Wokke BHA, Smolders J
    Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size.
    Brain. 2024 Jul 16:awae238. doi: 10.1093.
    PubMed    
    
    
    May 2024
36. JAMET Z, Mergaux C, Meras M, Bouchet D, et al
    NMDA receptor autoantibodies primarily impair the extrasynaptic compartment.
    Brain. 2024 May 17:awae163. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2024
37. HUANG J, Tengvall K, Bomfim Lima I, Hedstrom AK, et al
    Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis.
    Brain. 2024 Apr 17:awae110. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. ARELLANO G, Loda E, Chen Y, Neef T, et al
    Interferon-gamma controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder.
    Brain. 2024;147:1344-1361.
    PubMed     Abstract available
    
    
    March 2024
39. MAINERO C, Miscioscia A, Treaba CA
    Cortical remyelination in multiple sclerosis: a target for disease monitoring and intervention.
    Brain. 2024 Mar 27:awae083. doi: 10.1093.
    PubMed    
    
    
    January 2024
40. HERRANZ E, Treaba CA, Barletta VT, Mehndiratta A, et al
    Characterization of cortico-meningeal translocator protein expression in multiple sclerosis.
    Brain. 2024 Jan 30:awae030. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. LAZZAROTTO A, Hamzaoui M, Tonietto M, Dubessy AL, et al
    Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis.
    Brain. 2024 Jan 24:awae024. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. BAGNATO F, Sati P, Hemond CC, Elliott C, et al
    Imaging chronic active lesions in multiple sclerosis: a consensus statement.
    Brain. 2024 Jan 16:awae013. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. SCHWAB N
    Transcriptomics reveals CSF cellular composition in multiple sclerosis but detects no viral RNA.
    Brain. 2024 Jan 5:awae006. doi: 10.1093.
    PubMed    
    
    
    
44. QIN C, Chen M, Dong MH, Yang S, et al
    Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.
    Brain. 2024;147:163-176.
    PubMed     Abstract available
    
    
    
45. JAMANN H, Desu HL, Cui QL, Halaweh A, et al
    ALCAM on human oligodendrocytes mediates CD4 T cell adhesion.
    Brain. 2024;147:147-162.
    PubMed     Abstract available
    
    
    December 2023
46. MARZIALI LN, Hwang Y, Palmisano M, Cuenda A, et al
    p38gamma MAPK delays myelination and remyelination and is abundant in multiple sclerosis lesions.
    Brain. 2023 Dec 21:awad421. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. CALLEGARI I, Oechtering J, Schneider M, Perriot S, et al
    Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5.
    Brain. 2023 Dec 20:awad424. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. CREE BAC
    Herpes viral infection and the multiple sclerosis prodrome: is HHV-6A infection a second hit?
    Brain. 2023 Dec 18:awad418. doi: 10.1093.
    PubMed    
    
    
    
49. CLEAVER J, Jeffery K, Klenerman P, Lim M, et al
    The immunobiology of herpes simplex virus encephalitis and post-viral autoimmunity.
    Brain. 2023 Dec 13:awad419. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. BUTZKUEVEN H, Ponsonby AL, Stein MS, Lucas RM, et al
    Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.
    Brain. 2023 Dec 12:awad409. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. BAN M, Bredikhin D, Huang Y, Bonder MJ, et al
    Expression profiling of cerebrospinal fluid identifies dysregulated antiviral mechanisms in multiple sclerosis.
    Brain. 2023 Dec 1:awad404. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
52. KEDDIE S, Smyth D, Keh RYS, Chou MKL, et al
    Peripherin is a biomarker of axonal damage in peripheral nervous system disease.
    Brain. 2023;146:4562-4573.
    PubMed     Abstract available
    
    
    October 2023
53. GRUT V, Bistrom M, Salzer J, Stridh P, et al
    Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis.
    Brain. 2023 Oct 31:awad374. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. BERNARD HEALEY SA, Giovannoni G, Noyce A, Dobson R, et al
    Impact of multiple sclerosis risk alleles on the plasma proteome.
    Brain. 2023 Oct 18:awad363. doi: 10.1093.
    PubMed    
    
    
    
55. ALLEN NM, O'Rahelly M, Eymard B, Chouchane M, et al
    The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD).
    Brain. 2023;146:4233-4246.
    PubMed     Abstract available
    
    
    September 2023
56. MATSUMOTO Y, Kaneko K, Takahashi T, Takai Y, et al
    Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Brain. 2023;146:3938-3948.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.